• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / New Onset Psoriatic Arthritis Reported in Psoriasis Patients Treated with Efalizumab

New Onset Psoriatic Arthritis Reported in Psoriasis Patients Treated with Efalizumab

June 10, 2008 By Arthritis Center

Raptiva

The T-cell inhibitor efalizumab (Raptiva) has demonstrated efficacy in the treatment of moderate to severe plaque psoriasis.  However, it has not demonstrated efficacy for the treatment of psoriatic arthritis and, in one study, was associated with worsening of arthritis symptoms.  Only a minority of individuals with psoriasis have a concomitant inflammatory arthritis, making therapy with efalizumab an option for the treatment of a large number of psoriasis patients who have no articular involvement.  Here, Viguier et al (Arthritis Rheum 2008; 6(58):1796) report a case series of psoriasis patients with new-onset psoriatic arthritis temporally associated with therapy with efalizumab.

Methods

Members of 12 dermatology departments throughout France known to prescribe biologic therapy for psoriasis were queried for patients with inflammatory arthritis after initiating efalizumab therapy.  Follow-up questionnaires were then sent to patients and practitioners regarding past history of psoriasis and treatment, current and past articular and extra-articular signs and symptoms of psoriatic arthritis, and outcomes of arthritis symptoms with withdrawal or continuation of efalizumab.  ANA, RF, anti-CCP, and HLA-B27 were measured.

Results

Sixteen patients were identified with inflammatory arthritis symptoms after beginning efalizumab for psoriasis.  Patients were between 28 and 60 years of age (mean age 50 years) with an average duration of psoriasis of 16 years (range 3 to 37 years).  Only 1 patient had a family member with a history of inflammatory arthritis.  Arthritis symptoms began a median of 11 weeks after initiation of efalizumab (range 1 to 48 weeks).  Most commonly affected joints were, in descending order of frequency, knees, DIPs, spine, enthesitis, and dactylitis.  Almost half of patients demonstrated both axial and peripheral symptoms.  No patients had high titer RF, anti-CCP, or ANA.  Only one was HLA-B27 positive.  Only one patient had a past history of inflammatory joint involvement.

The severity of arthritis symptoms prompted discontinuation of efalizumab in 11 patients.  Most of these had improvement in symptoms after withdrawal, although NSAIDs and other DMARDs were required in all but one.  Two were treated with TNF inhibitors, with improvement, due to persistent disease activity after withdrawal.  Two patients had a re-challenge with efalizumab, both with relapse of arthritis within a time frame similar to initial onset.

An estimated 450 psoriasis patients received efalizumab in France over the time-period of the study, resulting in an estimated incidence of de novo psoriatic arthritis of 3.5%.

Conclusions

New onset psoriatic arthritis appears to be temporally associated with efalizumab therapy in patients with psoriasis.

Editorial Comment

Although still a rare occurrence, patients and prescribers of efalizumab should be aware of this potential side-effect.  Because some patients with psoriasis will go on to develop psoriatic arthritis during the course of their disease, often after years to decades of psoriasis, it is impossible to definitively determine whether the onset of inflammatory arthritis was causally related to the drug in every case, or the natural history of their underlying disease.  However, the close temporal relationship in many, but not all, cases and re-emergence of symptoms with re-challenge is supportive of a causal relationship in some patients.  Further experience with the drug may aid in identifying risk factors for incident psoriatic arthritis, such that the drug could be avoided in those at highest risk.  In addition, these findings may suggest clues to the pathogenesis and inter-relation between the mechanisms underlying skin psoriasis and psoriatic arthritis.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy